Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Conrad

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 7, 2012
Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communitiesYan Wei Lim, Robert Schmieder, Matthew Haynes, et al.
American Journal of Respiratory Cell and Molecular Biology|October 8, 2011
Case studies of the spatial heterogeneity of DNA viruses in the cystic fibrosis lungDana Willner, Matthew R Haynes, Mike Furlan, et al.
Implementation Science : IS|October 5, 2011
Design, rationale, and baseline characteristics of a cluster randomized controlled trial of pay for performance for hypertension treatment: study protocolLaura A Petersen, Tracy Urech, Kate Simpson, et al.
Journal of Inflammation (London, England)|November 2, 2010
HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppressionDouglas Conrad, Angela Wang, Raymond Pieters, et al.
Trials|June 21, 2015
Population-centered Risk- and Evidence-based Dental Interprofessional Care Team (PREDICT): study protocol for a randomized controlled trialJoana Cunha-Cruz, Peter Milgrom, R Michael Shirtcliff, et al.
Plos One|June 6, 2013
Mechanistic model of Rothia mucilaginosa adaptation toward persistence in the CF lung, based on a genome reconstructed from metagenomic dataYan Wei Lim, Robert Schmieder, Matthew Haynes, et al.
American Journal of Respiratory and Critical Care Medicine|April 8, 2014
The upper respiratory tract as a microbial source for pulmonary infections in cystic fibrosis. Parallels from island biogeographyKatrine L Whiteson, Barbara Bailey, Megan Bergkessel, et al.
Steroids|October 27, 2010
Novel components of the human metabolome: the identification, characterization and anti-inflammatory activity of two 5-androstene tetrolsClarence N Ahlem, Theodore M Page, Dominick L Auci, et al.
Science Advances|September 29, 2018
Niche partitioning of a pathogenic microbiome driven by chemical gradientsRobert A Quinn, William Comstock, Tianyu Zhang, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 8, 2016
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patientsPatrick A Flume, Donald R VanDevanter, Elizabeth E Morgan, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 7, 2012
Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communitiesYan Wei Lim, Robert Schmieder, Matthew Haynes, et al.
American Journal of Respiratory Cell and Molecular Biology|October 8, 2011
Case studies of the spatial heterogeneity of DNA viruses in the cystic fibrosis lungDana Willner, Matthew R Haynes, Mike Furlan, et al.
Implementation Science : IS|October 5, 2011
Design, rationale, and baseline characteristics of a cluster randomized controlled trial of pay for performance for hypertension treatment: study protocolLaura A Petersen, Tracy Urech, Kate Simpson, et al.
Journal of Inflammation (London, England)|November 2, 2010
HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppressionDouglas Conrad, Angela Wang, Raymond Pieters, et al.
Trials|June 21, 2015
Population-centered Risk- and Evidence-based Dental Interprofessional Care Team (PREDICT): study protocol for a randomized controlled trialJoana Cunha-Cruz, Peter Milgrom, R Michael Shirtcliff, et al.
Plos One|June 6, 2013
Mechanistic model of Rothia mucilaginosa adaptation toward persistence in the CF lung, based on a genome reconstructed from metagenomic dataYan Wei Lim, Robert Schmieder, Matthew Haynes, et al.
American Journal of Respiratory and Critical Care Medicine|April 8, 2014
The upper respiratory tract as a microbial source for pulmonary infections in cystic fibrosis. Parallels from island biogeographyKatrine L Whiteson, Barbara Bailey, Megan Bergkessel, et al.
Steroids|October 27, 2010
Novel components of the human metabolome: the identification, characterization and anti-inflammatory activity of two 5-androstene tetrolsClarence N Ahlem, Theodore M Page, Dominick L Auci, et al.
Science Advances|September 29, 2018
Niche partitioning of a pathogenic microbiome driven by chemical gradientsRobert A Quinn, William Comstock, Tianyu Zhang, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 8, 2016
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patientsPatrick A Flume, Donald R VanDevanter, Elizabeth E Morgan, et al.
Pageof 5